Mature B-NHL In Children, Adolescents And Young Adults - PubMed

Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

Mature B cell lymphomas account for approximately 60% of all cases of non-Hodgkin lymphoma (NHL) in children and adolescents and includes Burkitt lymphoma (BL), diffuse large B cell lymphoma (DLBCL) and other less common histologies. The outcome for patients treated with modern regimens in resource-intensive settings is excellent. Improvements in care have been accomplished through enhanced supportive therapy, including tumour lysis management and incremental refinement of chemotherapy backbones via cooperative group clinical trials in which patients receive risk group-specific intensive chemotherapy. More recent trials have established the safety and efficacy of immunotherapy. Ongoing work is required to address the substantial burden of acute therapy-related toxicity, as well as the identification of effective therapies for those patients with relapsed and refractory disease, for whom outcomes remain very poor. In this review we will summarize the results from recent therapeutic clinical trials, describe the evidence to support the inclusion of rituximab and review the rationale for the investigation of several new categories of novel agents for mature B cell lymphomas in children and adolescents.

Keywords: Burkitt lymphoma; diffuse large B cell lymphoma; mature B cell lymphoma; paediatric oncology; rituximab.

© 2019 British Society for Haematology and John Wiley & Sons Ltd.

PubMed Disclaimer

Publication types

• Review Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

MeSH terms

• Adolescent Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Age Factors Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Child Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Clinical Trials as Topic Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Combined Modality Therapy / adverse effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Combined Modality Therapy / methods Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Disease Management Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Disease Susceptibility Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Drug Resistance, Neoplasm Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, B-Cell / diagnosis* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, B-Cell / epidemiology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, B-Cell / mortality Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, B-Cell / therapy* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, Non-Hodgkin / diagnosis* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, Non-Hodgkin / epidemiology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, Non-Hodgkin / mortality Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, Non-Hodgkin / therapy* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Neoplasm Grading Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Neoplasm Staging Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Recurrence Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Risk Assessment Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Symptom Assessment Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Young Adult Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • ClinicalTrials.gov